A-Type Meningitis Vaccine

Choosing AIM Persistence Biopharmaceutical Co., Ltd. means choosing China's leading A-Type Meningitis Vaccine manufacturer and supplier. Xin'er Cong® quadrivalent meningococcal vaccine provides protection against four serotypes with a single dose, avoiding the health risks associated with cross-infection of different serotypes.

Why Choose Our Vaccine?

Compared to previously available meningococcal vaccines, we have made new research and development breakthroughs. Our A-Type Meningitis Vaccine, in addition to covering serotype A, also provides protection against three other serotypes. It can effectively address complex meningococcal meningitis outbreaks, offering more comprehensive protection to those vaccinated, and is a more cost-effective option.

Product Specifications

Instructions for Use

1. Open the A-Type Meningitis Vaccine vial, add the specified amount of diluent for reconstitution, shake well, and use immediately.

2. Administer the product by subcutaneous injection into the deltoid muscle attachment site on the outer aspect of the upper arm.

3. Dosage: One dose for children over 2 years of age and adults, with a dosage of 0.5 ml per person. Vaccination should be completed before the meningitis epidemic season.

4. Booster Immunization (Recommended abroad): For high-risk individuals in epidemic areas, especially children under 4 years of age at the time of initial vaccination, if they remain at high risk, a booster dose should be considered 2 to 3 years after the initial immunization. Although it has not been determined whether older children and adults require a booster dose, if antibody levels decline rapidly 2 to 3 years after vaccination, a booster dose should be considered within 3 to 5 years after the initial immunization.

Use Cases

Case: A 3-year-old boy had a fever for 6 hours, with a body temperature of 40.4℃, chills and fatigue

Early stage: Petechiae and ecchymosis appear on the trunk, with repeated fever and irritability

In the middle stage: Ecchymosis spreads to the limbs and the whole body, leading to septic shock, DIC and ARDS

Terminal stage: After 6 days of PICU treatment, the mental state returns to normal, but extensive skin lesions and necrosis occur, and dry gangrene appears on the fingers and toes

Immunization history: Received two doses of Group A meningococcal polysaccharide vaccine
Diagnosis: Blood culture: Positive for Meningococcus Y group (Cerebrospinal fluid culture was performed 3 days after antibiotic treatment, and the result was negative)

[1]Wang X, et al. Clinical and molecular characterization of the first culture-confirmed pediatric fulminant meningococcemia case caused by a serogroup Y clonal complex 23 strain in China. Vaccine. 2021 Jun 16:S0264-410X(21)00755-6.